Related Experiment Video
Updated: Feb 20, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Prospective Longitudinal Substance Use Patterns in Patients Preparing for Hepatitis C Treatment
Carol S North1, David E Pollio2, Omar T Sims2
1a The Altshuler Center for Education and Research at Metrocare Services and Department of Psychiatry , The University of Texas Southwestern Medical Center , Dallas , Texas , USA.
Investigating substance use in hepatitis C virus (HCV) patients found that alcohol, drug, and smoking patterns significantly impacted treatment outcomes. Tailoring interventions based on specific substance use is crucial for improving patient functioning and quality of life.
Area of Science:
- Addiction medicine
- Hepatology
- Psychosocial oncology
Background:
- Hepatitis C virus (HCV) treatment requires careful management of substance use.
- Understanding the independent trajectories of alcohol, drug, and smoking is vital for patient outcomes.
Purpose of the Study:
- To prospectively examine the independent courses of alcohol, drug, and smoking over 18 months in HCV patients.
- To assess the relationship between substance use patterns and functioning, coping, and quality of life in HCV patients.
Main Methods:
- Prospective study of 154 patients undergoing HCV treatment from a randomized controlled trial.
- Data collected via structured interviews, questionnaires, medical records, and urine testing over 18 months.
- Substance use patterns categorized as consistent abstinence, consistent use, or achieving abstinence.
Main Results:
- The overall sample showed improvement in functioning, coping, and quality of life.
- Specific substance use patterns (abstinence, continued use, achieving abstinence) were associated with distinct outcomes.
- Alcohol, drug, and smoking trajectories independently predicted HCV-related functioning, negative coping, and quality of life.
Conclusions:
- Different substances are associated with distinct clinical outcomes in HCV management.
- The findings suggest a need to unbundle substance types for tailored HCV patient care.
- Further research should explore the clinical utility of unbundling substances and the effects of use amounts.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Bioavailability Study Design: Healthy Subjects Versus Patients
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

